EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Myasthenia gravis: innovative therapies and new frontiers in research

Andrea Zovi, Roberto Langella, Lorenzo Martellone, Gerardo Miceli Sopo, Giacomo Polito, Antonio Vitiello

Drugs & Therapy Perspectives · 12.06.2026 · 42 (2) · 365-376

DOI: 10.1007/s40267-026-01246-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drugs & Therapy Perspectives, online erschienen am 12.06.2026. Verfasst von Andrea Zovi und 5 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myasthenia gravis (MG) is a rare acquired autoimmune disease affecting the neuromuscular junction, characterized by fluctuating muscle weakness that worsens with activity and improves with rest. The disease predominantly affects ocular, bulbar, neck, and limb muscles, with a prevalence of 1/5000 and incidence of 1/250,000–1/33,000 in Europe. Pathogenesis involves autoantibodies targeting post-synaptic membrane antigens, primarily acetylcholine receptors (AChR-Ab+, 80–90% of cases) or muscle-specific tyrosine kinase (MuSK-Ab+, 5–6% of cases). Current therapeutic approaches include symptomatic treatment with acetylcholinesterase inhibitors, immunosuppressive therapy with corticosteroids and non-steroidal immunosuppressants, and rescue therapies such as plasmapheresis for myasthenic crises. Approximately 5% of patients develop refractory MG, requiring targeted biological therapies including complement inhibitors (eculizumab, ravulizumab, zilucoplan) and neonatal Fc receptor (FcRn) inhibitors (efgartigimod alfa, rozanolixizumab). Recent clinical trials have demonstrated the efficacy of nipocalimab, a novel FcRn inhibitor, which recently received Food and Drug Administration (FDA) approval. Emerging chimeric antigen receptor (CAR)-T cell therapies targeting CD19-positive B cells represent an innovative approach inspired by oncological applications, with ongoing phase I/II studies (RESET-MG, KYSA-6) showing promising preliminary results in refractory cases. This review provides a comprehensive analysis of current therapeutic strategies, novel biological agents, and innovative cell-based therapies, highlighting the evolving therapeutic landscape of MG management.

Zitieren

APA

Zovi, A., Langella, R., Martellone, L., Sopo, G. M., Polito, G., & Vitiello, A. (2026). Myasthenia gravis: innovative therapies and new frontiers in research. Drugs & Therapy Perspectives, 42(2), 365-376. https://doi.org/10.1007/s40267-026-01246-9

Vancouver

Zovi A, Langella R, Martellone L, Sopo GM, Polito G, Vitiello A. Myasthenia gravis: innovative therapies and new frontiers in research. Drugs & Therapy Perspectives. 2026;42(2):365-376. doi:10.1007/s40267-026-01246-9

BibTeX
@article{Zovi2026,
  author = {Zovi, Andrea and Langella, Roberto and Martellone, Lorenzo and Sopo, Gerardo Miceli and Polito, Giacomo and Vitiello, Antonio},
  title = {Myasthenia gravis: innovative therapies and new frontiers in research},
  journal = {Drugs & Therapy Perspectives},
  year = {2026},
  volume = {42},
  number = {2},
  pages = {365--376},
  doi = {10.1007/s40267-026-01246-9}
}
Kostenlos starten →